Electroporation News and Research

RSS

IDT to demonstrate CRISPR expertise at European-focused events

As an advocate for the genomics age, Integrated DNA Technologies (IDT), will showcase its renowned CRISPR expertise at a series of European-focused events.

From Integrated DNA Technologies 22 Oct 2018

LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines

Applied DNA Sciences Inc. announced today that LineaRx, Inc., its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement with Takis S.R.L. and Evvivax S.R.L., biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.

20 Sep 2018

Academia and high tech companies join forces to increase production capacity for microfluidic systems

The University of Twente, Saxion University of Applied Sciences and four high tech companies are combining forces to increase the production capacity for microfluidic systems. As part of this pilot line project (“proeftuin”), they are improving access for SMEs to their facilities, including the MESA+ NanoLab and High Tech Factory.

From Micronit Microtechnologies B.V. 20 Apr 2018

New microcapsules represent promising vectors for application of genome-editing tools

Researchers from Tomsk Polytechnic University jointly with their colleagues from St. Petersburg, Hamburg and London have conducted a study in the course of which it was found out that polymer and hybrid silica-coated microcapsules are more efficient in genome-editing when applying CRISPR-Cas9 system.

6 Oct 2017

New DNA-based Zika vaccine demonstrates safety and ability to elicit immune response

A new generation DNA-based Zika vaccine is the first to demonstrate both safety and the ability to elicit an immune response against Zika in humans, according to new research from the Perelman School of Medicine at the University of Pennsylvania, conducted in partnership with The Wistar Institute, Inovio Pharmaceuticals, and GeneOne Life Science, Inc.

5 Oct 2017

New biomedical tool using nanoparticles could improve therapies for many diseases

A new biomedical tool using nanoparticles that deliver transient gene changes to targeted cells could make therapies for a variety of diseases -; including cancer, diabetes and HIV -; faster and cheaper to develop, and more customizable.

30 Aug 2017

Orlando Health deploys NanoKnife as new weapon in battle against pancreatic cancer

Oncologists at UF Health Cancer Center Orlando Health are deploying NanoKnife as a new weapon in the battle against pancreatic cancer.

1 Jun 2017

Graduate students develop novel microfluidic platform for monitoring single cell-level electroporation

Graduate students Mingde 'Jack' Zheng and Joseph Sherba have developed a novel, microfluidic platform for monitoring electroporation and molecular delivery at the single cell-level as part of a collaborative re-search team led by Professors Jeffrey Zahn and David Shreiber in the Department of Biomedical Engineer-ing and Professors Hao Lin and Jerry Shan in the Department of Mechanical and Aerospace Engineering at Rutgers,

3 Mar 2017

IDT offers cost-effective and most complete spectrum of CRISPR genome editing systems

Reflecting its drive to provide innovative solutions to the genomics community, Integrated DNA Technologies (IDT) is the first genomics company to develop and bring to market a complete ribonucleoprotein-based Cpf1 CRISPR system.

2 Feb 2017

New IDT webinar to highlight benefits of using RNP complexes for efficient genome modifications

Integrated DNA Technologies will host an informative webinar entitled ‘Ribonucleoprotein delivery of CRISPR-Cas9 reagents for increased gene editing efficiency’ on December 14, 2016.

9 Dec 2016

Noninvasive approach using pulsed electric fields may reduce scarring after burn injuries

A Massachusetts General Hospital research team has reported that repeated treatment with pulsed electric fields - a noninvasive procedure that does not generate heat - may help reduce the development of scarring.

10 Aug 2016

Researchers develop new non-invasive technique to prevent burn scars

A group of researchers from Tel Aviv University and Harvard University has devised a new non-invasive method to prevent burn scarring caused by the proliferation of collagen cells.

9 Aug 2016

New CRISPR-EZ method makes genome editing much easier in mice

University of California, Berkeley scientists have developed a quicker and more efficient method to alter the genes of mice with CRISPR-Cas9, simplifying a procedure growing in popularity because of the ease of using the new gene-editing tool.

28 May 2016

Researchers develop novel vaccine strategy to protect against Chikungunya virus

The Chikungunya virus (CHIKV) is transmitted through mosquitoes and causes fever and joint pain that can sometimes become severe and disabling. Outbreaks of the virus have already occurred in Africa, Asia, and Europe, and in late 2013, the virus was first seen in the Americas with the number of cases dramatically increased. No vaccine to prevent or treat this virus currently exists.

2 Apr 2016

RIKEN researchers discover how to reverse abnormal axonal development

Researchers at the RIKEN Brain Science Institute in Japan have discovered how to reverse the abnormal axonal development characteristic of CFEOM3, a congenital disease that affects the muscles that control eye movements.

19 Jan 2016

Interpretation of images starts in the retina

Tübingen researchers have shown that image processing in the eye is more extensive than previously thought. They investigated the channels that transmit information from the eye to the brain.

7 Jan 2016

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company's ongoing clinical trials (SB-728-1101 Cohort 3* and SB-728-mR-1401) of SB-728-T, which is being developed for the functional control of HIV/AIDS.

11 Dec 2015

Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Use of irreversible electroporation (IRE) doubles the survival time for patients with locally advanced pancreatic cancer say researchers at the University of Louisville in a paper in the September edition of the Annals of Surgery.

25 Aug 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC).

16 Jun 2015